Sangamo says Chapter 11 and auditor exit delay Q2 10-Q filing

• Sangamo filed a Form 12b-25 to delay its Form 10-Q for the quarter ended June 30, 2026.
• It expects to miss both the original deadline and the SEC’s five-day extension.
• The delay stems from its Chapter 11 process, which began June 23, 2026, straining limited finance and accounting staff.
• Ernst & Young’s engagement ended June 25, 2026, leaving the company without an independent auditor.
• Management cannot estimate when the Form 10-Q will be filed; results are expected to shift sharply due to restructuring-related costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sangamo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-354282), on August 17, 2026, and is solely responsible for the information contained therein.